MTOR and gastric cancer: To our knowledge, this is the first report that describes a strong inhibitory activity of dual PI3K/mTOR inhibitor BEZ235 in HER2-positive in vitro and in vivo gastric cancer patient-derived xenografts, and this finding can be utilized to design future clinical trials.